News Page

HMPV & Immunity: Why Immunomodulators Matter More Than Ever

Human metapneumovirus (hMPV) is a single-stranded RNA virus belonging to the Pneumoviridae family. Its genome spans approximately 13.35 kilobases and encodes eight genes responsible for synthesizing nine proteins, including nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), transcription enhancer protein (M2), small hydrophobic protein (SH), attachment glycoprotein (G), and RNA-dependent RNA polymerase (L). Among these, the matrix protein plays a vital structural role and is secreted in a soluble form by infected cells, triggering the release of inflammatory cytokines. Variations in the F gene allow hMPV to be classified into genetic groups A and B, further subdivided into sublineages like A1, A2.1, A2.2.1, A2.2.2, B1, and B2. Emerging subtypes such as A2.2.1 and A2.2.2 reflect the genetic evolution of the virus.

Impact on Pediatric Populations

hMPV is a significant contributor to acute respiratory infections (ARIs), a leading global health issue linked to 1.9–2.2 million deaths annually. Developing nations experience the highest burden, with children being disproportionately affected due to their underdeveloped immune systems. Research in India indicates that hMPV is implicated in 4–12% of acute respiratory tract infections (ARTIs).

In children, hMPV is the second most common cause of bronchiolitis, followed by respiratory syncytial virus (RSV). Symptoms vary from mild presentations like runny nose, cough, and fever to severe conditions, including bronchiolitis, pneumonia, and acute respiratory distress syndrome (ARDS). Coinfections with other pathogens, such as RSV and influenza, can exacerbate disease severity. Additionally, hMPV can worsen existing conditions like asthma and chronic respiratory illnesses, highlighting the need for timely intervention.

Management Strategies and Emerging Alternatives

Currently, no specific antiviral treatment is approved for hMPV. As a result, management strategies are primarily supportive. These include oxygen therapy to address hypoxemia in severe cases, bronchodilators used sparingly to alleviate wheezing, and corticosteroids to reduce airway inflammation in more severe instances. Ribavirin may be used off-label in immunocompromised patients with severe infections, though its use is not widespread. Additionally, monoclonal antibodies targeting the F protein are being evaluated in clinical trials as potential therapies. 

Preventive measures, including improved hygiene practices, isolation of infected individuals, and the development of experimental vaccines targeting the F protein, are also critical to current strategies.

Alternative Therapies for Immune Resilience

The absence of targeted antivirals underscores the importance of immune resilience therapies. Alternative approaches involving bioactive compounds with immunomodulatory and anti-inflammatory properties can complement traditional care. These therapies aim to:

• Strengthen the body’s defenses against respiratory infections.
• Accelerate recovery when used alongside conventional treatments.
• Minimize recurrence by addressing immune deficiencies.

For example, Septilin, a phytopharmaceutical formulation, is a notable immunity-enhancing alternative. It possesses immunomodulatory, antioxidant, anti-inflammatory, and antimicrobial properties. 

It constitutes polysaccharides, which may activate the properdin system and increase the chemotaxis of polymorphs. This leads to increased accumulation of polymorphs at the site of infection, resulting in phagocytosis and subsequent destruction of the pathogens. Key ingredients include Tinospora cordifolia, Emblica officinalis, and Glycyrrhiza glabra, which contribute to:

• Enhanced immune activity through macrophage activation, increased antibody production, and improved phagocytosis.
• Antiviral and antibacterial effects against pathogens like Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
• Anti-inflammatory actions that alleviate airway inflammation and control cytokine storms.

Clinical studies suggest that Septilin supports the management of respiratory infections by boosting immune defenses, expediting recovery, and reducing recurrence. For instance, a study published in the Indian Journal of Clinical Practice (2010) reported significant improvements in 75% of patients with upper respiratory tract infections following Septilin therapy.

In conclusion, a comprehensive approach combining supportive care, preventive measures, and immune-boosting therapies can effectively address the health burden of hMPV. Integrating alternatives like Septilin into standard care bridges existing gaps, enhances recovery, and reduces complications. For pediatric patients, such a multi-faceted strategy is vital in mitigating the impact of hMPV and ensuring better health outcomes.

References: 

• Sachdeva, Amit, and Nasim Ahmed. "Human Metapneumovirus in India (HMPV): Unveiling the Silent Respiratory Threat and Forging a Path to Resilient Healthcare Solutions." public health 8: 11.
• Deval, Hirawati, et al. "Human metapneumovirus (hMPV): an associated etiology of severe acute respiratory infection in children of Eastern Uttar Pradesh, India." Access Microbiology 6.9 (2024): 000829-v4.
• Yu, Jian, et al. "Clinical epidemiological features of hMPV infection in children with acute respiratory tract infection." Archives of Clinical Psychiatry 50.6 (2023).
• Iragamreddy, Venugopal Reddy. “Human Metapneumovirus (HMPV): A Comprehensive Review of its Impact on Pediatric and General Populations.” International Journal for Multidisciplinary Research. 7 (1) (2025).
• Panda, Swagatika, et al. "Human metapneumovirus: a review of an important respiratory pathogen." International journal of infectious diseases 25 (2014): 45-52.
• Praveen Kumar, V., G. Kuttan, and R. Kuttan. "Immunomodulatory activity of Septilin." Probe 21.2 (1982): 101-104.
• Nigam, P., et al. "Septilin Upper respiratory tract infections." The Medicine and Surgery 2 (1985): 28.
• Kshirsagar, Medha, et al. "Clinical efficacy and safety of Septilin tablets in respiratory tract infections: A Meta-analysis." Indian J ClinPract 20.8 (2010): 595-600.